Search for a networks
An Open-label, Multi-center, Phase I-Ib/II Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma (coordination)
- Type of network : Multinational clinical trials
- Geographic coverage : Global
- Funding body(ies) : -
- Sponsor : Novartis pharma services ag
Last update: April 2011
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.